瑞康医药1月30日获融资买入1506.55万元，融资余额2.44亿元

Group 1 - The core viewpoint of the news is that Ruikang Pharmaceutical has experienced a decline in stock price and financial performance, with significant changes in financing and shareholder metrics [1][2]. - On January 30, Ruikang Pharmaceutical's stock fell by 1.76%, with a trading volume of 210 million yuan. The financing buy-in amount was 15.07 million yuan, while the financing repayment was 23.70 million yuan, resulting in a net financing outflow of 8.63 million yuan [1]. - As of January 30, the total balance of margin trading for Ruikang Pharmaceutical was 244 million yuan, which accounts for 4.85% of its circulating market value, indicating a high level compared to the past year [1]. - The company has a significant margin balance, with a margin repayment of 5,700 shares and a margin sell-out of 5,200 shares on January 30, with a margin balance of 444,200 yuan, also at a high level compared to the past year [1]. - Ruikang Pharmaceutical's main business includes direct sales of pharmaceuticals (80.73% of revenue), medical devices (17.70%), mobile healthcare (0.67%), and other services [1]. Group 2 - As of October 31, the number of shareholders for Ruikang Pharmaceutical was 72,300, a decrease of 0.82% from the previous period, while the average circulating shares per person increased by 0.83% to 18,879 shares [2]. - For the period from January to September 2025, Ruikang Pharmaceutical reported a revenue of 5.407 billion yuan, a year-on-year decrease of 10.73%, and a net profit attributable to shareholders of 12.14 million yuan, down 68.73% year-on-year [2]. - Since its A-share listing, Ruikang Pharmaceutical has distributed a total of 393 million yuan in dividends, with 36.03 million yuan distributed over the past three years [3].